On ECHEMI
Home > Drugs > Merro Pharmaceutical Co., Ltd.
Merro Pharmaceutical Co., Ltd.
  • Founded in:

    2015-06-11
  • Country:

    China China
  • Address:

    No. 9, Yingsheng Road, Ganjingzi District, Dalian City, Liaoning Province
  • Tax NO.:

    912102007169138094
  • Registered Funds:

    350 million yuan
  • Website:

  • Email:

Related Drugs
Fukangning Tablets
White peony root, motherwort, angelica, cyperus rotundus, notoginseng, codonopsis pilosula, ophiopogon japonicus, mugwort (charcoal).
Name Description Content CAS NO. Registered Holders
PAEONIAE RADIX ALBA

0
Motherwort Herb P.E.

0
Angelicae Sinensis Radix

0
CYPERI RHIZOMA

0
NOTOGINSENG RADIX ET RHIZOMA

0
Codonopsis

0
Ophiopogonis Radix

0
Mugwort (charcoal)

0
Erythromycin Lactobionate for Injection
Erythromycin lactobionate.
Name Description Content CAS NO. Registered Holders
ERYTHROMYCIN LACTOBIONATE (200 MG)

This product belongs to the macrolide antibiotics, which is a water-soluble erythromycin lactobionate. It has antibacterial activity against Staphylococcus, various groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. may also be sensitive to this product. This product also has antibacterial activity against various anaerobic bacteria except Bacteroides fragilis and Fusobacterium; it also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can pass through the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis. Erythromycin is only effective against bacteria that actively divide.

More

This product belongs to the macrolide antibiotics, which is a water-soluble erythromycin lactobionate. It has antibacterial activity against Staphylococcus, various groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. may also be sensitive to this product. This product also has antibacterial activity against various anaerobic bacteria except Bacteroides fragilis and Fusobacterium; it also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can pass through the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis. Erythromycin is only effective against bacteria that actively divide.

3847-29-8 17
Ozagre
Name Description Content CAS NO. Registered Holders
Ozagrel

Extract from the above information

More

Extract from the above information

82571-53-7 29
Ozagre
Name Description Content CAS NO. Registered Holders
Ozagrel

No specific pharmacological effects mentioned

More

No specific pharmacological effects mentioned

82571-53-7 29
Labetalol Hydrochloride Tablets
Active ingredient: Labetalol hydrochloride.
Name Description Content CAS NO. Registered Holders
Labetalol hydrochloride

A drug that has both alpha and beta receptor blocking effects. It has weak intrinsic activity and membrane stabilizing effects. The effect of blocking beta receptors is 4-8 times that of blocking alpha receptors; the effect of blocking beta1 receptors is 1/4 of propranolol, and the effect of blocking beta2 receptors is 1/17-1/11 of propranolol. This product has a slightly stronger effect in blocking beta1 receptors than in blocking beta2 receptors. At equivalent doses, its heart rate slowing effect is milder than that of propranolol, and its antihypertensive effect occurs faster. The vasodilation caused by this product blocking alpha receptors is also involved in the antihypertensive and anti-anginal mechanisms. Compared with simple beta receptor blockers, this drug has a stronger antihypertensive effect during standing and exercise tests. In addition, it can increase renal blood flow, while propranolol reduces it.

More

A drug that has both alpha and beta receptor blocking effects. It has weak intrinsic activity and membrane stabilizing effects. The effect of blocking beta receptors is 4-8 times that of blocking alpha receptors; the effect of blocking beta1 receptors is 1/4 of propranolol, and the effect of blocking beta2 receptors is 1/17-1/11 of propranolol. This product has a slightly stronger effect in blocking beta1 receptors than in blocking beta2 receptors. At equivalent doses, its heart rate slowing effect is milder than that of propranolol, and its antihypertensive effect occurs faster. The vasodilation caused by this product blocking alpha receptors is also involved in the antihypertensive and anti-anginal mechanisms. Compared with simple beta receptor blockers, this drug has a stronger antihypertensive effect during standing and exercise tests. In addition, it can increase renal blood flow, while propranolol reduces it.

32780-64-6 35
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.